HER2 overexpression is associated with a more aggressive phenotype in human breast cancer, and treatment with the anti-HER2 monoclonal antibody trastuzumab has achieved response rates of up to 60% in the clinical setting [91]. This evidence concerns the gene ERBB2 and breast cancer.